(Bloomberg) -- Daiichi Sankyo Co. shares jumped by the most in a year after a drug it developed with AstraZeneca Plc showed favorable results in a trial for a common type of breast cancer.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionIndia-Canada Clash Should Be a Wakeup CallWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundIndians Have Five Days to Deposit $3 Billion in Soon-to-Be-Withdrawn BanknotesCorzine Plans to Shut Hedge Fund and Return Cap